Targeted therapy for fusion-driven high-risk acute leukemia

Yana Pikman and Kimberly Stegmaier


Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.

  • Submitted April 23, 2018.
  • Accepted July 14, 2018.
View Full Text